Shots:
- Revolution Medicines has started treatment in global P-III (RASolute 303) trial assessing daraxonrasib (PO) as monotx. & in combination with CT for the treatment of pts with previously untreated metastatic PDAC, irrespective of tumor RAS genotype
- The trial will assess PFS & OS as 1EP, while the key 2EPs include additional measures of antitumor activity, safety & tolerability, & patient reported outcomes
- Daraxonrasib, direct RAS(ON) multi-selective inhibitor, is being evaluated in 4 global P-III trials, incl. three trials in PDAC & one in NSCLC
Ref: Revolution Medicines | Image: Revolution Medicines | Press Release
Related News: Royalty Pharma Purchases Revolution Medicines’ Royalty Rights of Daraxonrasib for ~2B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
